Does Excessive Body Mass Affect the RhGH Therapy Outcomes in GHD Children?

Overview

Journal Pediatr Endocrinol Diabetes Metab

Publisher Termedia

Specialty Pediatrics

Date 2024 Oct 25

PMID 39451184

Authors

Tomasz Maroszczuk

Jan Maciej Kapala

Aleksandra Sitarz

Anna Kacka-Stanczak

Dorota Charemska

Affiliations

Soon will be listed here.

Abstract

Introduction: For 35 years, recombinant human growth hormone (rhGH) has been successfully used worldwide to treat children with short stature related to growth hormone deficiency (GHD). Growth hormone therapy requires an individual approach to the patient due to varying responses to the treatment. Excessive body weight is one of the factors influencing the response.

Aim Of The Study: To evaluate the impact of excessive body mass on rhGH therapy effectiveness in GHD children.

Material And Methods: 165 short-statured children with isolated GHD (mean age 10.72 ±3.33 years), treated with rhGH for at least one year (mean follow-up 4.32 ±1.80 years), were separated into 3 groups based on their BMI standard deviation score (SDS). Bone age, height, weight, insulin-like growth factor 1 level, and rhGH dose were obtained up to 10 years with one-year intervals.

Results: The mean change in height SDS in the first year was 0.52 ±0.41 SD and 0.60 ±0.32 SD for normal and excessive body weight children, respectively. The mean height velocity, based on the height SDS measured over the consecutive 5 years, was 0.44±0.25 SD/year for the normal-weight group and 0.32 ±0.24 SD/year for the excessive body weight group (p < 0.1).

Conclusions: Excess body weight has a significant impact on rhGH therapy outcomes. This correlates with the height increase in the first year of observation; however, long-term observation has shown that children diagnosed with overweight or obesity achieve significantly worse results compared to their normal-weight peers.

References

van Dam E, Roelfsema F, Helmerhorst F, Frolich M, Meinders A, Veldhuis J . Low amplitude and disorderly spontaneous growth hormone release in obese women with or without polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87(9):4225-30. DOI: 10.1210/jc.2002-012006. View

Thomas M, Massa G, Craen M, de Zegher F, Bourguignon J, Heinrichs C . Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol. 2004; 151(1):67-72. DOI: 10.1530/eje.0.1510067. View

Cole T, Hindmarsh P, Dunger D . Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency. Arch Dis Child. 2004; 89(11):1024-7. PMC: 1719706. DOI: 10.1136/adc.2003.043406. View

Bright G, Morris P, Rosenfeld R . When Is a Positive Test for Pediatric Growth Hormone Deficiency a True-Positive Test?. Horm Res Paediatr. 2021; 94(11-12):399-405. DOI: 10.1159/000521281. View

Bidlingmaier M, Friedrich N, Emeny R, Spranger J, Wolthers O, Roswall J . Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014; 99(5):1712-21. DOI: 10.1210/jc.2013-3059. View

Stovitz S, Demerath E, Hannan P, Lytle L, Himes J . Growing into obesity: patterns of height growth in those who become normal weight, overweight, or obese as young adults. Am J Hum Biol. 2011; 23(5):635-41. PMC: 3152584. DOI: 10.1002/ajhb.21191. View

Yang A, Cho S, Kwak M, Kim S, Park S, Jin D . Impact of BMI on peak growth hormone responses to provocative tests and therapeutic outcome in children with growth hormone deficiency. Sci Rep. 2019; 9(1):16181. PMC: 6838176. DOI: 10.1038/s41598-019-52644-1. View

Shalitin S, Gat-Yablonski G . Associations of Obesity with Linear Growth and Puberty. Horm Res Paediatr. 2021; 95(2):120-136. DOI: 10.1159/000516171. View

Hawcutt D, Bellis J, Price V, Povall A, Newland P, Richardson P . Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height. PLoS One. 2017; 12(7):e0181567. PMC: 5513545. DOI: 10.1371/journal.pone.0181567. View

10.

Iranmanesh A, Lizarralde G, Veldhuis J . Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991; 73(5):1081-8. DOI: 10.1210/jcem-73-5-1081. View

11.

Clasey J, Weltman A, Patrie J, Weltman J, Pezzoli S, Bouchard C . Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab. 2001; 86(8):3845-52. DOI: 10.1210/jcem.86.8.7731. View

12.

Stochholm K, Kiess W . Long-term safety of growth hormone-A combined registry analysis. Clin Endocrinol (Oxf). 2017; 88(4):515-528. DOI: 10.1111/cen.13502. View

13.

Frohman L, Downs T, Chomczynski P . Regulation of growth hormone secretion. Front Neuroendocrinol. 1992; 13(4):344-405. View

14.

Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M . Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994; 125(1):29-35. DOI: 10.1016/s0022-3476(94)70117-2. View

15.

Kulaga Z, Litwin M, Tkaczyk M, Rozdzynska A, Barwicka K, Grajda A . The height-, weight-, and BMI-for-age of Polish school-aged children and adolescents relative to international and local growth references. BMC Public Health. 2010; 10:109. PMC: 2837854. DOI: 10.1186/1471-2458-10-109. View

16.

Bao X, Shi Y, Du Y, Liu R, Deng J, Gao S . Prevalence of growth hormone deficiency of children in Beijing. Chin Med J (Engl). 1992; 105(5):401-5. View

17.

Veldhuis J, Iranmanesh A, Weltman A . Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine. 1997; 7(1):41-8. DOI: 10.1007/BF02778061. View

18.

Coelho R, Brook C, Preece M, Stanhope R, Dattani M, Hindmarsh P . A randomised study of two doses of biosynthetic human growth hormone on final height of pubertal children with growth hormone deficiency. Horm Res. 2008; 70(2):85-8. DOI: 10.1159/000139149. View

19.

Lewinski A, Smyczynska J, Stawerska R, Hilczer M, Stasiak M, Bednarczuk T . National Program of Severe Growth Hormone Deficiency Treatment in Adults and Adolescents after Completion of Growth Promoting Therapy. Endokrynol Pol. 2018; 69(5):468-524. DOI: 10.5603/EP.a2018.0054. View

20.

Chung S . Growth and Puberty in Obese Children and Implications of Body Composition. J Obes Metab Syndr. 2019; 26(4):243-250. PMC: 6489471. DOI: 10.7570/jomes.2017.26.4.243. View